TIDMAGL
Angle PLC
05 December 2023
For immediate release 5 December 2023
ANGLE plc ("the Company")
ANGLE LAUNCHES PORTRAIT + CTC KIT AT San Antonio Breast Cancer
Symposium
ANGLE's Portrait+ CTC staining kit combines the power of
Parsortix(R) technology with an optimised immunofluorescent
assay
The test is designed for highly accurate, repeatable, and
precise results allowing CTC identification, characterisation and
enumeration
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company with innovative circulating tumour cell (CTC) diagnostic
solutions for use in research, drug development and clinical
oncology, is delighted to announce the launch of its Portrait(R) +
CTC staining kit at the San Antonio Breast Cancer Symposium
(SABCS).
The Portrait+ CTC staining kit is a ready-to-use kit for the
identification, characterisation and enumeration of epithelial and
mesenchymal cancer cells including those undergoing
epithelial-to-mesenchymal transition (EMT). EMT is a key transition
step in cancer cells, and is associated with tumour progression,
the development of drug resistance, and metastasis.
This launch follows extensive development, optimisation and
validation of the kit to provide advanced immunofluorescent (IF)
staining of CTCs harvested from a patient blood sample by the
Parsortix technology . The performance of current CTC protocols
being used by academic and research institutions varies
considerably. ANGLE has developed its test for reliable repeatable
results with a fully validated, standardised protocol to make it
easy for customers to adopt. Key features of the product
include:
-- use of a direct staining technique and an optimised, vivid
dye combination to ensure high signal intensity while maintaining
high analytical specificity and sensitivity
-- p re-mixed and freeze-dried antibodies for ease-of-use and long-term storage
-- inclusion of a CellKeep(TM) slide, a unique CTC harvesting
technology developed by ANGLE to maximise the retention of CTCs
harvested from blood samples for imaging. The slide confines the
harvested CTCs to a small area, reducing the volume of antibodies
required for staining, decreasing imaging time and cost and
minimising cell loss between the Parsortix system and the imaging
process.
It is well established that the number of CTCs is not only
prognostic to overall survival, but can monitor drug treatment
response, detect early development of (micro)metastases and assess
therapeutic response earlier than traditional imaging methods.
The Portrait+ CTC staining kit can be used to enumerate CTCs
harvested using the epitope independent Parsortix technology in
multiple cancer types including breast, lung, prostate and ovarian
cancers.
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"ANGLE's Portrait+ CTC staining kit provides investigators with
accurate, repeatable, and precise identification of CTCs and hence
has the potential to optimise study protocols and minimise
cost.
We are now beginning an active promotion of this test to
academic and translational research customers. The standardisation
and simplification of the cell staining process and the new
innovations to retain the harvested cells on the microscope slide
will expand the market for Parsortix technology as it will make it
easier for customers to adopt the solution in their own
laboratories."
For further information:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Berenberg (NOMAD and Joint Broker)
Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800
Jefferies (Joint Broker)
Thomas Bective, Shaam Vora +44 (0) 20 7029 8000
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
For Research Use Only. Not for use in diagnostic procedures.
For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative
circulating tumour cell (CTC) diagnostic solutions for use in
research, drug development and clinical oncology using a simple
blood sample. ANGLE's FDA cleared and patent protected circulating
tumour cell (CTC) harvesting technology known as the Parsortix(R)
PC1 System enables complete downstream analysis of the sample
including whole cell imaging and proteomic analysis and full
genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic
products and clinical services. Diagnostic products include the
Parsortix(R) system and associated consumables. The clinical
services business is offered through ANGLE's GCP-compliant
laborator y in the UK. Services include custom made assay
development and clinical trial testing for pharma.
Over 90 peer-reviewed publications have demonstrated the
performance of the Parsortix system. For more information, visit
www.angleplc.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRATIBRTMTAMBLJ
(END) Dow Jones Newswires
December 05, 2023 02:00 ET (07:00 GMT)
Angle (LSE:AGL)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Angle (LSE:AGL)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024